Skip to content

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

Comparison Efficacy of Mirogabalin and Pregabalin in Total Knee Arthroplasty. a Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06328062
Enrollment
80
Registered
2024-03-25
Start date
2024-04-01
Completion date
2026-08-31
Last updated
2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Pain Postoperative, Total Knee Arthroplasty

Keywords

mirogabalin, pregabalin, pain postoperative, TKA

Brief summary

The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty. The main question\[s\] it aims to answer are: • Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty. Participants will randomized to mirogabalin or pregabalin group and will take the drug for 2 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.

Detailed description

After surgery is complete, you will be randomly assigned to receive painkillers Mirogabalin or Pregabalin along with other standard medications. Surgery by Mirogabalin group: Participants received 5 mg of mirogabalin, one tablet taken twice a day, after breakfast and dinner, for 2 weeks. In the pregabalin group: Participants received 75 mg of pregabalin, one tablet taken daily before bedtime, for 2 weeks.

Interventions

Participants will receive 5 mg of mirogabalin, twice a day, after breakfast and dinner, for 2 weeks.

DRUGPregabalin

Participants will receive 75 mg of pregabalin, once a day before bedtime, for 2 weeks.

Sponsors

Thammasat University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Age 50-85 years old 2. Unilateral primary osteoarthritis undergoing primary TKA 3. ASA I-III

Exclusion criteria

1. GFR \<60 2. Allergy to drug in this study 3. Cannot underwent spinal anesthesia and adductor canal block 4. Taking gabapentinoid within 3 months before surgery 5. History of previous knee surgery 6. Severe liver disease

Design outcomes

Primary

MeasureTime frameDescription
Pain scoreEvery 6 hours after surgery for 2 days, then twice a day for 2 weeks, then once a week until 12 week after surgery.Visual analog scale at rest and motion (0-100 points, 0 mean best, 100 mean worst)

Secondary

MeasureTime frameDescription
Morphine consumption72 hours after surgeryTotal morphine consumption in hospital (mg)
Range of motion24 hour, 48 hour, 2 week, 6 week and 12 week after surgeryUsing long arm goniometer (degrees)
Knee society score2 week, 6 week and 12 week after surgeryreport in point (0-100, 0 mean worst, 100 mean best)
Knee injury and Osteoarthritis Outcome Score (KOOS)2 week, 6 week and 12 week after surgeryreport in point (0-100, 0 mean worst, 100 mean best)
Sedation score24 hour, 48 hour, 2 week, 6 week and 12 week after surgeryreport in point (0-100, 0 mean best, 100 mean worst)
Incidence of Somnolence and dizzinesseveryday until 14 days then once a week until 12 weeks after surgeryUsing scale "Mild, moderate and severe"
Total hospital stayup to 1 weekNumber of days the patient stays for surgery

Countries

Thailand

Contacts

CONTACTYot Tanariyakul, M.D.
y.tanariyakul@gmail.com+66863930257

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 8, 2026